Ceregene, Inc., a San Diego-based biotechnology company focused on the delivery of nervous system growth (neurotrophic) factors for the treatment of neurodegenerative and retinal disorders using gene delivery, has closed a $11.5m Series D financing.
The round was co-led by Hamilton BioVentures and Alta Partners, with participation from MPM Capital and Investor Growth Capital.
Ceregene intends to use the funds to conduct its Phase 2b clinical study of CERE-120 for the treatment of Parkinson’s disease.
In conjunction with the investment, Kerry Dance, Ph.D., Managing Director of Hamilton BioVentures will join the company’s board of directors. Dr. Dance was President of General Atomics Corporation and has been involved in the biotechnology industry for over 10 years.
Ceregene also submitted three projects as part of the Therapeutic Discovery Tax Credit program and was awarded $244,479 on each, for a total of $733,437.
These funds, which add adds to the recent support from The Michael J. Fox Foundation, will help the company advance its Parkinson’s disease program, its Phase 2 study of CERE-110 for the treatment of Alzheimer’s disease and its ocular disease program.